Alterity Therapeutics (ATHE) Accumulated Expenses (2011 - 2025)

Alterity Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $89173.9 for Q2 2025.

• On a quarterly basis, Accumulated Expenses fell 18.52% year-over-year to $89173.9 in Q2 2025; TTM through Jun 2025 was $89173.9, a 18.52% decrease from a year earlier, with the FY2025 full-year figure at $89173.9, down 18.52% from the prior year.
• Accumulated Expenses eased to $89173.9 in Q2 2025 per ATHE's latest filing, from $109439.6 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $222126.0 in Q2 2023 and bottomed at $89173.9 in Q2 2025.
• The 3-year median for Accumulated Expenses is $109439.6 (2024), against an average of $140246.5.
• Across the five-year window, Accumulated Expenses plunged 50.73% in 2024 and slipped 18.52% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $222126.0 in 2023, then plunged by 50.73% to $109439.6 in 2024, then decreased by 18.52% to $89173.9 in 2025.
• Per Business Quant, the three latest ATHE Accumulated Expenses figures stand at $89173.9 (Q2 2025), $109439.6 (Q2 2024), and $222126.0 (Q2 2023).